---
title: "RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286484178.md"
description: "RemeGen Co. Ltd. has approved a cash management plan to invest up to RMB2.5 billion of idle funds in wealth management products. Recently, the company entered agreements with HTSC to invest RMB453 million in low-to-medium risk, fixed-income products, which may enhance interest income and demonstrate prudent treasury management. This transaction is disclosed under Hong Kong listing rules. The latest analyst rating for RemeGen (HK:9995) is a Buy, with a price target of HK$129.00."
datetime: "2026-05-14T23:39:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286484178.md)
  - [en](https://longbridge.com/en/news/286484178.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286484178.md)
---

# RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.

RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to RMB2.5 billion of idle self-owned funds to purchase wealth management products, reflecting an effort to enhance returns on surplus liquidity without diverting capital from core operations. On 14 May 2026, the company entered four agreements with HTSC to invest a total of RMB453 million in low-to-medium risk, fixed-income wealth management products, a move that constitutes a discloseable transaction under Hong Kong listing rules and may modestly improve interest income while signaling prudent treasury management to investors.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

**More about RemeGen Co. Ltd. Class H**

RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The company focuses on developing and commercializing innovative therapies and operates in the healthcare and life sciences sector, deploying its financial resources to support research, operations, and strategic growth in its core drug development business.

**Average Trading Volume:** 4,162,412

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$69.16B

Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [601688.CN](https://longbridge.com/en/quote/601688.CN.md)
- [06886.HK](https://longbridge.com/en/quote/06886.HK.md)
- [HTSC.UK](https://longbridge.com/en/quote/HTSC.UK.md)

## Related News & Research

- [RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer](https://longbridge.com/en/news/282374325.md)
- [BOCOM International Holdings Company Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)](https://longbridge.com/en/news/273178637.md)
- [Hisense Home Appliances Deploys RMB1.81 Billion into Chongqing Trust Wealth Products](https://longbridge.com/en/news/286888326.md)
- [Jacobio Boosts Share Buybacks and Liquidity as Oncology Pipeline Advances](https://longbridge.com/en/news/286835606.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)